JP2019517536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517536A5 JP2019517536A5 JP2018563716A JP2018563716A JP2019517536A5 JP 2019517536 A5 JP2019517536 A5 JP 2019517536A5 JP 2018563716 A JP2018563716 A JP 2018563716A JP 2018563716 A JP2018563716 A JP 2018563716A JP 2019517536 A5 JP2019517536 A5 JP 2019517536A5
- Authority
- JP
- Japan
- Prior art keywords
- flt3 receptor
- neuropathic
- pain
- daily dose
- receptor inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 37
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 37
- 108091006082 receptor inhibitors Proteins 0.000 claims 34
- 208000004296 neuralgia Diseases 0.000 claims 20
- 208000021722 neuropathic pain Diseases 0.000 claims 20
- 208000002193 Pain Diseases 0.000 claims 17
- 230000002981 neuropathic effect Effects 0.000 claims 14
- 208000000094 Chronic Pain Diseases 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 229960001796 sunitinib Drugs 0.000 claims 4
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 4
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 claims 3
- 229950006304 gilteritinib Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 3
- 229950010895 midostaurin Drugs 0.000 claims 3
- 229950001626 quizartinib Drugs 0.000 claims 3
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000011552 rat model Methods 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- GKEYKDOLBLYGRB-LGMDPLHJSA-N 5-[2-(diethylamino)ethyl]-2-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1h-pyrrolo[3,2-c]pyridin-4-one Chemical compound O=C\1NC2=CC=C(F)C=C2C/1=C/C(N1)=C(C)C2=C1CCN(CCN(CC)CC)C2=O GKEYKDOLBLYGRB-LGMDPLHJSA-N 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- MLIFNJABMANKEU-UHFFFAOYSA-N cep-5214 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCO)C4=C3CC2=C1 MLIFNJABMANKEU-UHFFFAOYSA-N 0.000 claims 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000007933 dermal patch Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940125199 famitinib Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- UHEBDUAFKQHUBV-UHFFFAOYSA-N jspy-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000001032 spinal nerve Anatomy 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000007939 sustained release tablet Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 238000012447 xenograft mouse model Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305669.0 | 2016-06-08 | ||
| EP16305669.0A EP3254698A1 (en) | 2016-06-08 | 2016-06-08 | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| PCT/EP2017/063935 WO2017211937A1 (en) | 2016-06-08 | 2017-06-08 | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517536A JP2019517536A (ja) | 2019-06-24 |
| JP2019517536A5 true JP2019517536A5 (enExample) | 2020-05-07 |
| JP7134097B2 JP7134097B2 (ja) | 2022-09-09 |
Family
ID=56134285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563716A Active JP7134097B2 (ja) | 2016-06-08 | 2017-06-08 | 神経障害性疼痛の治療のための低用量ｆｌｔ３受容体阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10709687B2 (enExample) |
| EP (2) | EP3254698A1 (enExample) |
| JP (1) | JP7134097B2 (enExample) |
| HU (1) | HUE062092T2 (enExample) |
| WO (1) | WO2017211937A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3955920A1 (en) * | 2019-04-16 | 2022-02-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| KR102231446B1 (ko) * | 2021-01-21 | 2021-03-24 | (주) 와이디생명과학 | 베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물 |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE303998T1 (de) | 2000-10-17 | 2005-09-15 | Merck & Co Inc | Oral aktive salze mit tyrosinkinaseaktivität |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| DE60213842T2 (de) | 2001-10-30 | 2007-09-06 | Novartis Ag | Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung |
| EP1458713B1 (en) | 2001-12-27 | 2005-08-24 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AU2003262642B2 (en) | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| EP1539754A4 (en) | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | BENZIMIDAZOCHINOLINONE AND ITS USE |
| EP1566379A4 (en) | 2002-10-29 | 2005-11-09 | Kirin Brewery | CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF |
| SG148864A1 (en) | 2002-11-13 | 2009-01-29 | Chiron Corp | Methods of treating cancer and related methods |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| DE60326646D1 (de) | 2002-12-18 | 2009-04-23 | Vertex Pharma | Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| AU2006304897B2 (en) | 2005-10-18 | 2012-07-12 | Janssen Pharmaceutica N.V. | Method of inhibiting FLT3 kinase |
| KR101449057B1 (ko) | 2006-03-17 | 2014-10-10 | 암비트 바이오사이언시즈 코포레이션 | 질환 치료용 이미다졸로티아졸 화합물 |
| EP2596795A1 (en) | 2007-11-08 | 2013-05-29 | Ambit Biosciences Corporation | Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
| MX2010007973A (es) | 2008-02-01 | 2010-11-09 | Akinion Pharmaceuticals Ab | Derivados de pirazina y su uso como inhibidores de proteina cinasa. |
| HUE045270T2 (hu) | 2010-01-05 | 2019-12-30 | Inst Nat Sante Rech Med | FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére |
| BR112017002001B1 (pt) * | 2014-07-31 | 2022-10-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compostos e composição farmacêutica |
-
2016
- 2016-06-08 EP EP16305669.0A patent/EP3254698A1/en not_active Withdrawn
-
2017
- 2017-06-08 US US16/307,968 patent/US10709687B2/en active Active
- 2017-06-08 WO PCT/EP2017/063935 patent/WO2017211937A1/en not_active Ceased
- 2017-06-08 JP JP2018563716A patent/JP7134097B2/ja active Active
- 2017-06-08 HU HUE17727913A patent/HUE062092T2/hu unknown
- 2017-06-08 EP EP17727913.0A patent/EP3468602B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536176A5 (enExample) | ||
| JP2017057230A5 (enExample) | ||
| JP2009536147A5 (enExample) | ||
| JP2019517536A5 (enExample) | ||
| JP2016540021A5 (enExample) | ||
| JP2008520736A5 (enExample) | ||
| JP2013541595A5 (enExample) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| ATE543489T1 (de) | Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür | |
| JP2017506624A5 (enExample) | ||
| JP2015528471A5 (enExample) | ||
| JP2016185995A5 (enExample) | ||
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| JP2018507243A5 (enExample) | ||
| HRP20170734T1 (hr) | Povećana biodostupnost lijeka u terapiji naltreksonom | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| JP2018039810A5 (enExample) | ||
| WO2007031887A3 (en) | Extended release pharmaceutical composition of metformin and a process for producing it | |
| JP2011516544A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| CN106924388B8 (zh) | 一种治疗失眠的药物组合物及其制备方法、制剂与应用 | |
| HRP20251123T1 (hr) | Ekopipam za liječenje touretteovog sindroma | |
| JP2014503589A5 (enExample) | ||
| JP2023531930A5 (enExample) |